72 related articles for article (PubMed ID: 36763223)
21. Persistence and adherence to dutasteride/tamsulosin fixed-dose versus free-combination alpha blocker/5ARI therapy in patients with benign prostate hyperplasia in Germany
.
Eisen C; Lulic Z; Palacios-Moreno JM; Adalig B; Hennig M; Cortes V; Gilg F; Kostev K
Int J Clin Pharmacol Ther; 2020 Jan; 58(1):37-49. PubMed ID: 31670653
[TBL] [Abstract][Full Text] [Related]
22. Effects of Withdrawing α1-Blocker from Combination Therapy with α1-Blocker and 5α-Reductase Inhibitor in Patients with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia: A Prospective and Comparative Trial Using Urodynamics.
Matsukawa Y; Takai S; Funahashi Y; Majima T; Kato M; Yamamoto T; Gotoh M
J Urol; 2017 Oct; 198(4):905-912. PubMed ID: 28499730
[TBL] [Abstract][Full Text] [Related]
23. Drug adherence and clinical outcomes for patients under pharmacological therapy for lower urinary tract symptoms related to benign prostatic hyperplasia: population-based cohort study.
Cindolo L; Pirozzi L; Fanizza C; Romero M; Tubaro A; Autorino R; De Nunzio C; Schips L
Eur Urol; 2015 Sep; 68(3):418-25. PubMed ID: 25465970
[TBL] [Abstract][Full Text] [Related]
24. Clinical effects of discontinuing 5-alpha reductase inhibitor in patients with benign prostatic hyperplasia.
Kim W; Jung JH; Kang TW; Song JM; Chung HC
Korean J Urol; 2014 Jan; 55(1):52-6. PubMed ID: 24466398
[TBL] [Abstract][Full Text] [Related]
25. Progression of lower urinary tract symptoms after discontinuation of 1 medication from 2-year combined alpha-blocker and 5-alpha-reductase inhibitor therapy for benign prostatic hyperplasia in men--a randomized multicenter study.
Lin VC; Liao CH; Kuo HC
Urology; 2014 Feb; 83(2):416-21. PubMed ID: 24332123
[TBL] [Abstract][Full Text] [Related]
26. Adherence to 5-alpha reductase inhibitor therapy for benign prostatic hyperplasia: clinical and economic outcomes.
Gruschkus S; Poston S; Eaddy M; Chaudhari S
P T; 2012 Aug; 37(8):464-70. PubMed ID: 23091339
[TBL] [Abstract][Full Text] [Related]
27. BPH: unmet needs in managing LUTS--a European perspective.
De Nunzio C; Tubaro A
Nat Rev Urol; 2011 Nov; 9(1):9-10. PubMed ID: 22124306
[No Abstract] [Full Text] [Related]
28. Effect of Shifting from Combination Therapy to Monotherapy of α-Blockers or 5α-Reductase Inhibitors on Prostate Volume and Symptoms in Patients with Benign Prostatic Hyperplasia.
Kim HW; Moon DG; Kim HM; Hwang JH; Kim SC; Nam SG; Park JT
Korean J Urol; 2011 Oct; 52(10):681-6. PubMed ID: 22087362
[TBL] [Abstract][Full Text] [Related]
29. Outcomes and general health-related quality of life among patients medically treated in general daily practice for lower urinary tract symptoms due to benign prostatic hyperplasia.
Fourcade RO; Lacoin F; Rouprêt M; Slama A; Le Fur C; Michel E; Sitbon A; Cotté FE
World J Urol; 2012 Jun; 30(3):419-26. PubMed ID: 21892656
[TBL] [Abstract][Full Text] [Related]
30. Urologist compliance with AUA best practice guidelines for benign prostatic hyperplasia in Medicare population.
Strope SA; Elliott SP; Saigal CS; Smith A; Wilt TJ; Wei JT;
Urology; 2011 Jul; 78(1):3-9. PubMed ID: 21601254
[TBL] [Abstract][Full Text] [Related]
31. Risk stratification for benign prostatic hyperplasia (BPH) treatment.
Emberton M; Fitzpatrick JM; Rees J
BJU Int; 2011 Mar; 107(6):876-80. PubMed ID: 21265993
[TBL] [Abstract][Full Text] [Related]
32. The effects of dutasteride, tamsulosin, and the combination on storage and voiding in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the Combination of Avodart and Tamsulosin study.
Becher E; Roehrborn CG; Siami P; Gagnier RP; Wilson TH; Montorsi F
Prostate Cancer Prostatic Dis; 2009; 12(4):369-74. PubMed ID: 19901936
[TBL] [Abstract][Full Text] [Related]
33. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study.
Roehrborn CG; Siami P; Barkin J; Damião R; Major-Walker K; Nandy I; Morrill BB; Gagnier RP; Montorsi F;
Eur Urol; 2010 Jan; 57(1):123-31. PubMed ID: 19825505
[TBL] [Abstract][Full Text] [Related]
34. The effects of dutasteride, tamsulosin and combination therapy on lower urinary tract symptoms in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the CombAT study.
Roehrborn CG; Siami P; Barkin J; Damião R; Major-Walker K; Morrill B; Montorsi F;
J Urol; 2008 Feb; 179(2):616-21; discussion 621. PubMed ID: 18082216
[TBL] [Abstract][Full Text] [Related]
35. The long-term outcome of medical therapy for BPH.
Madersbacher S; Marszalek M; Lackner J; Berger P; Schatzl G
Eur Urol; 2007 Jun; 51(6):1522-33. PubMed ID: 17416456
[TBL] [Abstract][Full Text] [Related]
36. The interpretation of serum prostate specific antigen in men receiving 5alpha-reductase inhibitors: a review and clinical recommendations.
Marks LS; Andriole GL; Fitzpatrick JM; Schulman CC; Roehrborn CG
J Urol; 2006 Sep; 176(3):868-74. PubMed ID: 16890642
[TBL] [Abstract][Full Text] [Related]
37. Medication adherence and persistence: a comprehensive review.
Krueger KP; Berger BA; Felkey B
Adv Ther; 2005; 22(4):313-56. PubMed ID: 16418141
[TBL] [Abstract][Full Text] [Related]
38. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia.
McConnell JD; Roehrborn CG; Bautista OM; Andriole GL; Dixon CM; Kusek JW; Lepor H; McVary KT; Nyberg LM; Clarke HS; Crawford ED; Diokno A; Foley JP; Foster HE; Jacobs SC; Kaplan SA; Kreder KJ; Lieber MM; Lucia MS; Miller GJ; Menon M; Milam DF; Ramsdell JW; Schenkman NS; Slawin KM; Smith JA;
N Engl J Med; 2003 Dec; 349(25):2387-98. PubMed ID: 14681504
[TBL] [Abstract][Full Text] [Related]
39. Benign prostatic hyperplasia: a progressive disease of aging men.
Emberton M; Andriole GL; de la Rosette J; Djavan B; Hoefner K; Vela Navarrete R; Nordling J; Roehrborn C; Schulman C; Teillac P; Tubaro A; Nickel JC
Urology; 2003 Feb; 61(2):267-73. PubMed ID: 12597928
[No Abstract] [Full Text] [Related]
40. Natural history of prostatism: risk factors for acute urinary retention.
Jacobsen SJ; Jacobson DJ; Girman CJ; Roberts RO; Rhodes T; Guess HA; Lieber MM
J Urol; 1997 Aug; 158(2):481-7. PubMed ID: 9224329
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
